ES2422269T3 - Composiciones de análogos de G-CSF y métodos - Google Patents

Composiciones de análogos de G-CSF y métodos

Info

Publication number
ES2422269T3
ES2422269T3 ES10011853T ES10011853T ES2422269T3 ES 2422269 T3 ES2422269 T3 ES 2422269T3 ES 10011853 T ES10011853 T ES 10011853T ES 10011853 T ES10011853 T ES 10011853T ES 2422269 T3 ES2422269 T3 ES 2422269T3
Authority
ES
Spain
Prior art keywords
analogs
csf
methods
another aspect
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10011853T
Other languages
English (en)
Inventor
Timothy Osslund
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21743861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2422269(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ES2422269T3 publication Critical patent/ES2422269T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)

Abstract

Un polipéptido de G-CSF de SEC ID Nº: 2 para uso en un método para tratar neutropenia, donde el polipéptido GCSFestá modificado en al menos una molécula de polietilenglicol unida indirectamente mediante otro resto químicocon el bucle CD en los aminoácidos 119-145, y donde la metionina N terminal como se expone en SEC ID Nº 2 esopcional.
ES10011853T 1993-01-28 1994-01-27 Composiciones de análogos de G-CSF y métodos Expired - Lifetime ES2422269T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/010,099 US5581476A (en) 1993-01-28 1993-01-28 Computer-based methods and articles of manufacture for preparing G-CSF analogs

Publications (1)

Publication Number Publication Date
ES2422269T3 true ES2422269T3 (es) 2013-09-10

Family

ID=21743861

Family Applications (3)

Application Number Title Priority Date Filing Date
ES10011853T Expired - Lifetime ES2422269T3 (es) 1993-01-28 1994-01-27 Composiciones de análogos de G-CSF y métodos
ES04019074T Expired - Lifetime ES2382927T3 (es) 1993-01-28 1994-01-27 Composiciones de análogos de G-CSF y métodos
ES94101207T Expired - Lifetime ES2150951T3 (es) 1993-01-28 1994-01-27 Composiciones de analogos de g-csf y metodos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES04019074T Expired - Lifetime ES2382927T3 (es) 1993-01-28 1994-01-27 Composiciones de análogos de G-CSF y métodos
ES94101207T Expired - Lifetime ES2150951T3 (es) 1993-01-28 1994-01-27 Composiciones de analogos de g-csf y metodos.

Country Status (22)

Country Link
US (6) US5581476A (es)
EP (8) EP1482046B1 (es)
JP (7) JPH08506018A (es)
KR (2) KR100375274B1 (es)
CN (3) CN1495197B (es)
AT (2) ATE195552T1 (es)
AU (2) AU697451B2 (es)
CA (4) CA2711007C (es)
DE (1) DE69425516T2 (es)
DK (3) DK0612846T3 (es)
ES (3) ES2422269T3 (es)
FI (2) FI120769B (es)
GR (1) GR3034745T3 (es)
HK (2) HK1009288A1 (es)
IL (6) IL124112A (es)
LU (1) LU92265I2 (es)
LV (1) LV12642B (es)
NO (3) NO952974L (es)
NZ (5) NZ332188A (es)
PT (3) PT2345724E (es)
WO (1) WO1994017185A1 (es)
ZA (1) ZA94568B (es)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
ATE135370T1 (de) * 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3708151B2 (ja) * 1994-12-15 2005-10-19 協和醗酵工業株式会社 Ｐｅｇ化したヒト顆粒球コロニー刺激因子の定量法
JP2000501744A (ja) * 1996-01-22 2000-02-15 クリエイティブ バイオモレキゥルズ，インコーポレーテッド モルホゲン類似体およびその製法
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
US5835382A (en) * 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
US6128582A (en) * 1996-04-30 2000-10-03 Vertex Pharmaceuticals Incorporated Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them
ES2297889T3 (es) * 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
CN1061992C (zh) * 1997-11-19 2001-02-14 蒋永平 新的重组人粒细胞集落刺激因子及其药物组合物
EP1073683B1 (en) * 1998-04-30 2005-12-28 Tanox, Inc. G-csf receptor agonist antibodies and screening method therefor
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US7208473B2 (en) * 1999-01-06 2007-04-24 Xencor, Inc. Nucleic acids and protein variants of hG-CSF with granulopoietic activity
JP4092081B2 (ja) * 1999-01-06 2008-05-28 ゼンコー・インコーポレイテッド 顆粒球形成活性を有するｇ−ｃｓｆ変異体相当核酸およびタンパク質
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
HU228488B1 (en) * 1999-01-29 2013-03-28 Amgen Inc Gcsf conjugates
US6500418B1 (en) * 1999-02-12 2002-12-31 The Washington University Stimulating neutrophil function to treat inflammatory bowel disease
JP2000319298A (ja) * 1999-03-04 2000-11-21 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質複合体の結晶、構造座標、及び構造座標の使用
US7244396B2 (en) 1999-04-06 2007-07-17 Uab Research Foundation Method for preparation of microarrays for screening of crystal growth conditions
US7247490B2 (en) 1999-04-06 2007-07-24 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
EP1181548B1 (en) * 1999-04-06 2007-03-21 The University of Alabama at Birmingham Research Foundation Method for screening crystallization conditions in solution crystal growth
US20030022383A1 (en) * 1999-04-06 2003-01-30 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US7250305B2 (en) 2001-07-30 2007-07-31 Uab Research Foundation Use of dye to distinguish salt and protein crystals under microcrystallization conditions
US7214540B2 (en) * 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
WO2000068252A1 (en) * 1999-05-10 2000-11-16 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6296673B1 (en) * 1999-06-18 2001-10-02 The Regents Of The University Of California Methods and apparatus for performing array microcrystallizations
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US7058517B1 (en) 1999-06-25 2006-06-06 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
EP1200124B1 (en) * 1999-07-13 2008-09-10 Bolder Biotechnology, Inc. Erythropoietin-immunoglobulin fusion proteins
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6555660B2 (en) * 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
AR027509A1 (es) * 2000-01-10 2003-04-02 Maxygen Aps Conjugados g-csf
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) * 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
GB0008563D0 (en) * 2000-04-07 2000-05-24 Cambridge Discovery Chemistry Investigating different physical and/or chemical forms of materials
EP1043239B1 (en) * 2000-06-16 2004-02-04 VSI Holding A/S Container with collapsible sides
US6931326B1 (en) 2000-06-26 2005-08-16 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
US7792645B2 (en) * 2000-08-30 2010-09-07 The Salk Institute For Biological Studies Three-dimensional structure of chalcone isomerase and methods of use thereof
AU2001288220A1 (en) * 2000-09-07 2002-03-22 Eli Lilly And Company Hyperglycosylated polypeptides
CA2421760A1 (en) * 2000-09-08 2002-03-14 Massachusetts Institute Of Technology G-csf analog compositions and methods
WO2002036626A1 (en) * 2000-11-02 2002-05-10 Maxygen Aps Single-chain multimeric polypeptides
CA2440467A1 (en) * 2001-03-12 2002-09-19 Board Of Regents, University Of Texas System Ensemble-based strategy for the design of protein pharmaceuticals
DE10112825A1 (de) * 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
US7670429B2 (en) 2001-04-05 2010-03-02 The California Institute Of Technology High throughput screening of crystallization of materials
US6998219B2 (en) * 2001-06-27 2006-02-14 University Of South Florida Maskless photolithography for etching and deposition
JP4444652B2 (ja) * 2001-07-11 2010-03-31 マキシゲン・ホールディングズ・リミテッド Ｇ−ｃｓｆ結合体
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040247562A1 (en) * 2001-09-28 2004-12-09 Sang Yup Lee Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP2006507562A (ja) * 2002-05-23 2006-03-02 ザ ボード オブ レジェンツ−ザ ユニバーシティー オブ テキサス システム アンサンブルベースの構造エネルギーを使用した一塩基多型（ｓｎｐｓ）の意義の予測
WO2004005898A1 (en) * 2002-07-10 2004-01-15 Uab Research Foundation Method for distinguishing between biomolecule and non-biomolecule crystals
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
BR0314107A (pt) * 2002-09-11 2005-07-19 Fresenius Kabi De Gmbh Método de produção de derivados de hidroxialquil amido
DE10242076A1 (de) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
AU2003273413A1 (en) * 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
GEP20084486B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
JP2006519170A (ja) * 2002-12-26 2006-08-24 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
AU2004263274B2 (en) 2003-07-21 2009-11-05 Transgene S.A. Novel multifunctional cytokines
BRPI0412671A (pt) * 2003-08-08 2006-10-03 Fresenius Kabi De Gmbh conjugados de um polìmero e uma proteìna ligados por um grupo de ligação de oxima
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
DK2441465T3 (da) * 2003-10-24 2014-04-14 Nora Therapeutics Inc Præparater og fremgangsmåder til en sund graviditet
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
US20090226397A1 (en) 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20060122784A1 (en) * 2004-12-03 2006-06-08 Ishikawa Muriel Y System and method for augmenting a humoral immune response
CA2552241C (en) 2003-12-30 2013-10-01 Durect Corporation Co-polymeric devices for controlled release of active agents
TW200603818A (en) * 2004-03-11 2006-02-01 Fresenius Kabi De Gmbh Conjugates of hydroxyethyl starch and erythropoietin
AR048035A1 (es) 2004-03-11 2006-03-22 Fresenius Kabi De Gmbh Conjugados de almidon de hidroxialquilo y una proteina, preparados por aminacion reductora
AU2005269527B2 (en) 2004-07-26 2011-12-01 Pfenex Inc. Process for improved protein expression by strain engineering
EP1817047B1 (en) 2004-11-05 2012-02-08 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
WO2006063300A2 (en) * 2004-12-10 2006-06-15 Genentech, Inc. Crystal structure of hepatocyte growth factor activator complexed with kunitz domain inhibitor
WO2006067170A1 (en) 2004-12-23 2006-06-29 Laboratoires Serono S.A. G-csf polypeptides and uses thereof
EP1858543B1 (en) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylated granulocyte colony stimulating factor
KR100657749B1 (ko) * 2005-04-13 2006-12-20 씨제이 주식회사 인간 과립구 콜로니 형성인자 동종체 및 그 조성물
CN101193658B (zh) * 2005-06-01 2011-08-31 马克西根控股公司 聚乙二醇化g-csf多肽及其产生方法
KR100694994B1 (ko) * 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
KR100735784B1 (ko) 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
CA2618447C (en) * 2005-08-15 2015-06-02 Phares Pharmaceutical Research N.V. Crystal forms of astaxanthin
WO2007024940A2 (en) * 2005-08-22 2007-03-01 Dana-Farber Cancer Institute, Inc. Mitochondrial localization of muc1
US20070112804A1 (en) * 2005-11-07 2007-05-17 Desimas Bruce E Systems and methods for generating automated software workflows for biological testing
GB0605684D0 (en) * 2006-03-21 2006-05-03 Sicor Biotech Uab Method For Purifying Granulocyte-Colony Stimulating Factor
US8129345B2 (en) * 2006-07-20 2012-03-06 Dana-Farber Cancer Institute, Inc. MUC1-IκB kinase complexes and their activities
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
WO2008097844A2 (en) * 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
JP4375412B2 (ja) * 2007-02-19 2009-12-02 株式会社デンソー 蒸発器ユニット
CA2685326A1 (en) 2007-04-27 2008-11-06 Dow Global Technologies Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
KR20110016430A (ko) 2007-07-03 2011-02-17 암젠 인코퍼레이티드 봉입체 건량을 이용한 단백질 측정
HUE037633T2 (hu) 2007-07-09 2018-09-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
EP2185689A2 (en) 2007-08-09 2010-05-19 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
WO2009046015A2 (en) * 2007-09-30 2009-04-09 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US8570393B2 (en) * 2007-11-30 2013-10-29 Cognex Corporation System and method for processing image data relative to a focus of attention within the overall image
EP2070950A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
EP2070951A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Method for producing a hydroxyalkyl starch derivatives with two linkers
CN103694337B (zh) 2008-02-08 2016-03-02 Ambrx公司 经修饰瘦素多肽和其用途
ES2523030T3 (es) 2008-02-18 2014-11-20 Jiangsu Hengrui Medicine Co., Ltd. Un conjugado del G-CSF modificado por un polímero hidrosoluble
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
JP5667565B2 (ja) 2008-07-22 2015-02-12 メノジェニックス， インコーポレイテッド 閉経期、ホルモン変動および関節炎と関連する症状を治療するための組成物および方法
UA118536C2 (uk) * 2008-07-23 2019-02-11 Амбркс, Інк. Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
US9151289B2 (en) 2008-08-21 2015-10-06 Cummins Inc. Fuel pump
EA201990619A1 (ru) 2008-10-10 2019-07-31 Амген Инк. Fgf21 мутанты и их применение
AU2009305550B2 (en) 2008-10-17 2014-06-12 Dana-Farber Cancer Institute, Inc. MUC-1 cytoplasmic domain peptides as inhibitors of cancer
US9189670B2 (en) * 2009-02-11 2015-11-17 Cognex Corporation System and method for capturing and detecting symbology features and parameters
UY32607A (es) 2009-05-05 2010-12-31 Amgen Inc Mutantes de fgf21 y usos del mismo
EP2427207B1 (en) 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
JP2012530493A (ja) * 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド キメラポリペプチドおよびその使用
MX2012006397A (es) 2009-12-02 2012-11-30 Amgen Inc PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
CN107056929A (zh) 2009-12-21 2017-08-18 Ambrx 公司 经过修饰的猪促生长素多肽和其用途
WO2011115819A2 (en) 2010-03-15 2011-09-22 Genus Oncology, Llc Small molecule inhibitors of muc1 and methods of identifying the same
EP2550366B1 (en) 2010-03-23 2014-11-12 IMBA-Institut für Molekulare Biotechnologie GmbH Methods for identifying inhibitors of the type iii secretion system
CA2796055A1 (en) 2010-04-15 2011-10-20 Amgen Inc. Human fgf receptor and .beta.-klotho binding proteins
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
PT2621519T (pt) 2010-09-28 2017-10-04 Aegerion Pharmaceuticals Inc Polipéptido de fusão de leptina-abd com duração de ação melhorada
US8889630B2 (en) 2011-12-23 2014-11-18 Carlos Lopez Method for hair regrowth using Granulocyte-Colony Stimulating Factor
WO2014045126A2 (en) 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
PL3524618T3 (pl) 2013-03-15 2023-07-10 GLAdiator Biosciences, Inc. Domeny gla jako środki ukierunkowujące
LT6161B (lt) 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
WO2015057724A1 (en) 2013-10-14 2015-04-23 Nora Therapeutics, Inc. Use of g-csf for treating or preventing villitis of unknown etiology in a human female
WO2016201448A2 (en) * 2015-06-11 2016-12-15 Prolong Pharmaceuticals, LLC Pegylated granulocyte colony stimulating factor (gcsf)
EP3365360A1 (en) * 2015-10-19 2018-08-29 Sandoz AG Improved coding sequence for human g-csf
EP3679129A1 (en) 2017-09-05 2020-07-15 GLAdiator Biosciences, Inc. A method of intracellular delivery
CN108384747A (zh) * 2018-03-05 2018-08-10 安徽省农业科学院园艺研究所 表达狂犬抗体的cho细胞无血清悬浮培养方法
CA3151471A1 (en) * 2019-10-08 2021-04-15 Gesa VOLKERS Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same
US20230227520A1 (en) 2019-12-17 2023-07-20 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel g-csf mimics and their applications

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS6263335A (ja) * 1985-09-13 1987-03-20 Fuji Photo Film Co Ltd 化学反応情報の処理方法
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
DK203187A (da) * 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
JPH01500483A (ja) * 1986-08-11 1989-02-23 シタス　コーポレイション Ｇ‐ｃｓｆ及びそのミューテインの発現
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
DK174044B1 (da) * 1986-12-23 2002-05-06 Kyowa Hakko Kogyo Kk Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid.......
US4853871A (en) * 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
GB2213821B (en) * 1987-12-23 1992-01-02 British Bio Technology Synthetic human granulocyte colony stimulating factor gene
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
EP0344796B1 (en) * 1988-06-03 1994-09-21 Chugai Seiyaku Kabushiki Kaisha Crystalline human granulocyte colony stimulating factor and process for preparing the same
US5025388A (en) * 1988-08-26 1991-06-18 Cramer Richard D Iii Comparative molecular field analysis (CoMFA)
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
US5265030A (en) * 1990-04-24 1993-11-23 Scripps Clinic And Research Foundation System and method for determining three-dimensional structures of proteins
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
AU651152B2 (en) * 1990-08-29 1994-07-14 Genetics Institute, Llc Multidomain hematopoiesis stimulators
US5124297A (en) 1990-12-07 1992-06-23 Amoco Corporation Olefin polymerization and copolymerization catalyst
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
WO1992016555A1 (en) * 1991-03-18 1992-10-01 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5157736A (en) * 1991-04-19 1992-10-20 International Business Machines Corporation Apparatus and method for optical recognition of chemical graphics
US5386507A (en) * 1991-07-18 1995-01-31 Teig; Steven L. Computer graphics system for selectively modelling molecules and investigating the chemical and physical properties thereof
DE69227693T2 (de) * 1991-08-30 1999-07-22 Fred Hutchinson Cancer Research Center, Seattle, Wash. Hybride cytokine
JP2638359B2 (ja) * 1991-11-26 1997-08-06 富士通株式会社 分子動力学法の拘束条件作成装置
ATE195553T1 (de) * 1992-06-09 2000-09-15 Chiron Corp Kristallisierung von m-csf
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US6153183A (en) 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
AU5670994A (en) 1992-11-24 1994-06-22 G.D. Searle & Co. Interleukin-3 (il-3) mutant polypeptides
US5772992A (en) 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US5424963A (en) * 1992-11-25 1995-06-13 Photon Research Associates, Inc. Molecular dynamics simulation method and apparatus
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CA2212006A1 (en) 1995-02-03 1996-08-08 G.D. Searle & Co. Novel c-mpl ligands
US6017523A (en) 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
EP0870027A1 (en) 1995-10-05 1998-10-14 G.D. Searle & Co. Novel c-mpl receptor agonists
US6100070A (en) 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
EP0859843A1 (en) 1995-10-05 1998-08-26 G.D. Searle & Co. Novel g-csf receptor agonists
US6066318A (en) 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
CN1590407A (zh) 1995-10-05 2005-03-09 G.D.瑟尔公司 多功能性造血受体激动剂
AU725547B2 (en) 1996-10-25 2000-10-12 G.D. Searle & Co. Multi-functional chimeric hematopoietic receptor agonists
US6660257B1 (en) 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
US5969105A (en) 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
JP2001527396A (ja) 1997-04-11 2001-12-25 ジー．ディー．サール アンド カンパニー ｆｌｔ３リガンドキメラタンパク質
AU6246599A (en) 1998-09-25 2000-04-17 G.D. Searle & Co. Method of producing permuteins by scanning permutagenesis
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
CN102180944A (zh) * 2001-10-10 2011-09-14 诺和诺德公司 肽的重构和糖缀合

Also Published As

Publication number Publication date
IL145994A (en) 2010-12-30
DK1482046T3 (da) 2012-06-25
NZ504840A (en) 2001-11-30
FI953593A0 (fi) 1995-07-27
EP0965638A2 (en) 1999-12-22
JPH08506018A (ja) 1996-07-02
NO952974D0 (no) 1995-07-27
EP0965638A3 (en) 2000-02-23
EP1233065A1 (en) 2002-08-21
IL145994A0 (en) 2002-07-25
IL124112A (en) 2006-12-10
EP2345724A1 (en) 2011-07-20
ES2150951T3 (es) 2000-12-16
FI20090384A (fi) 2009-10-21
FI953593A (fi) 1995-07-27
PT612846E (pt) 2001-01-31
CN1495197B (zh) 2013-01-16
JP2004113243A (ja) 2004-04-15
DE69425516D1 (de) 2000-09-21
CN1970571A (zh) 2007-05-30
US6261550B1 (en) 2001-07-17
CA2381489C (en) 2010-10-19
IL108446A0 (en) 1994-04-12
GR3034745T3 (en) 2001-02-28
KR100390338B1 (ko) 2003-07-07
US20030171559A1 (en) 2003-09-11
US6632426B2 (en) 2003-10-14
IL125398A0 (en) 1999-03-12
CA2239360C (en) 2002-07-16
CA2153896A1 (en) 1994-08-04
JP2011207885A (ja) 2011-10-20
CA2381489A1 (en) 1994-08-04
CA2711007C (en) 2012-10-02
DK0612846T3 (da) 2000-10-09
PT1482046E (pt) 2012-06-06
DE69425516T2 (de) 2001-06-13
DK2345724T3 (da) 2013-09-30
EP0890640A2 (en) 1999-01-13
ES2382927T3 (es) 2012-06-14
EP1482046A2 (en) 2004-12-01
WO1994017185A1 (en) 1994-08-04
CA2711007A1 (en) 1994-08-04
IL124111A (en) 2002-09-12
EP1482046A3 (en) 2005-01-05
EP1482046B1 (en) 2012-04-11
HK1107356A1 (en) 2008-04-03
US20050260154A1 (en) 2005-11-24
NO20031497D0 (no) 2003-04-02
EP1482045A2 (en) 2004-12-01
NO20031497L (no) 2003-04-02
AU6095794A (en) 1994-08-15
US5581476A (en) 1996-12-03
ZA94568B (en) 1994-09-12
US20010016191A1 (en) 2001-08-23
KR960700341A (ko) 1996-01-19
AU8197098A (en) 1998-10-15
KR100375274B1 (ko) 2003-06-11
JP2010059170A (ja) 2010-03-18
LV12642B (en) 2001-09-20
NZ513422A (en) 2002-09-27
PT2345724E (pt) 2013-08-22
US8058398B2 (en) 2011-11-15
JP2009057368A (ja) 2009-03-19
NO20093489L (no) 1995-09-28
NZ261765A (en) 1997-10-24
EP0612846B1 (en) 2000-08-16
IL108446A (en) 2003-01-12
HK1009288A1 (en) 1999-05-28
EP2345724B1 (en) 2013-07-03
EP1482045A3 (en) 2004-12-29
FI123078B (fi) 2012-10-31
CN1118572C (zh) 2003-08-20
ATE195552T1 (de) 2000-09-15
JP2006096762A (ja) 2006-04-13
CA2239360A1 (en) 1994-08-04
CN1495197A (zh) 2004-05-12
NZ314960A (en) 1999-01-28
LU92265I2 (fr) 2013-10-14
CN1970571B (zh) 2013-07-10
FI120769B (fi) 2010-02-26
NO952974L (no) 1995-09-28
EP0974655A2 (en) 2000-01-26
EP0890640A3 (en) 1999-03-24
NZ332188A (en) 2000-07-28
CN1132527A (zh) 1996-10-02
LV12642A (lv) 2001-04-20
AU697451B2 (en) 1998-10-08
ATE553199T1 (de) 2012-04-15
CA2153896C (en) 1999-01-12
US7381804B2 (en) 2008-06-03
EP0612846A1 (en) 1994-08-31
JP2006137762A (ja) 2006-06-01
EP0974655A3 (en) 2001-10-24
US5790421A (en) 1998-08-04

Similar Documents

Publication Publication Date Title
ES2150951T3 (es) Composiciones de analogos de g-csf y metodos.
FR2681786B1 (es)
NO960309L (no) Agonister og antagonister for humaninterleukin-10
FI863971A (fi) Farmaceutisk komposition anvaendbar vid behandling av leukopenia.
PT84089A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
DK12990D0 (da) Human granulocyt-makrofag-kolonistimulerende faktor og muteiner heraf